ବାମ୍ଲାନିଭିମାବ/ଇଟେସିଭିମାବ

ବାମ୍ଲାନିଭିମାବ/ଇଟେସିଭିମାବ
Combination of
Bamlanivimab	Monoclonal antibody
Etesevimab	Monoclonal antibody
Clinical data
data	US DailyMed: Bamlanivimab;
Routes of; administration	Intravenous
Legal status
Legal status	US: Unapproved (emergency use authorization);

ବାମ୍ଲାନିଭିମାବ/ଇଟେସିଭିମାବ ଏକ ଔଷଧ ମିଶ୍ରଣ ଯାହା କୋଭିଡ-୧୯ର ପ୍ରତିଷେଧ ଓ ଚିକିତ୍ସା ନିମନ୍ତେ ବ୍ୟବହୃତ ହୁଏ । ^[୪] ସେଗୁଡିକ ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଡାକ୍ତରଖାନାରେ ଭର୍ତ୍ତି ହେବା ଆବଶ୍ୟକ କରନ୍ତି ନାହିଁ କିନ୍ତୁ ଖରାପ ହେବାର ଆଶଙ୍କା ଅଧିକ ଥାଏ । ^[୪] ଓମିକ୍ରନ୍ ପ୍ରକାର ପାଇଁ ଏହା ବହୁତ କମ୍ ପ୍ରଭାବଶାଳୀ । ^[୫] ଏହା ଶିରାରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ । ^[୪]

ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଞ୍ଜେକ୍ସନ୍ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଏବଂ ଆନାଫାଇଲକ୍ସିସ୍ ସହିତ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ^[୬] ^[୭] ଗର୍ଭାବସ୍ଥାରେ ନିରାପତ୍ତାର କୌଣସି ପ୍ରମାଣ ନଥିଲେ ମଧ୍ୟ ଏହିପରି ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଇପାରେ । ^[୭] ବାମ୍ଲାନିଭିମାବ ଏବଂ ଇଟେସେଭିମାବର ମିଶ୍ରଣ ହେଉଛି ଦୁଇଟି ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଏସଏଆରଏସ-କୋଭି-୨ (SARS - CoV - 2)ର ପୃଷ୍ଠ ସ୍ପାଇକ୍ ପ୍ରୋଟିନର ବିଭିନ୍ନ ଅଂଶ ସହିତ ବନ୍ଧନ ଯୁକ୍ତ ହୋଇଥାଏ । ^[୪]

ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ମିଶ୍ରଣର ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ପ୍ରାଧିକରଣ ଅଛି । ^[୪] ୟୁରୋପରେ ଅନୁମୋଦନ ପାଇଁ ଅନୁରୋଧ ପ୍ରତ୍ୟାହାର କରାଯାଇଛି। ^[୮] ଜାନୁୟାରୀ ୨୦୨୨ ସୁଦ୍ଧା, ସେମାନେ ପ୍ରତିରୋଧର କମ୍ ହାର ସହିତ ଯୁକ୍ତରାଷ୍ଟ୍ରର କିଛି ଅଂଶରେ ବଣ୍ଟନ ଜାରି ରଖିଥିଲେ । ^[୪] ^[୯] ୨୦୨୧ ସୁଦ୍ଧା ଏହି ମିଶ୍ରଣ ପାଇଁ ଆମେରିକା ସରକାର ପ୍ରାୟ ୨,୧୦୦ ଡଲାର ଖର୍ଚ୍ଚ କରିଛନ୍ତି।

ଆଧାର

↑ "FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 10 February 2021. Archived from the original on 10 February 2021. Retrieved 9 February 2021. This article incorporates text from this source, which is in the public domain.
↑ "FDA authorizes bamlanivimab and etesevimab for COVID-19". U.S. Food and Drug Administration. 16 September 2021. Archived from the original on 17 September 2021. Retrieved 16 September 2021.
↑ "Emergency Use Authorization 094" (PDF). U.S. Food and Drug Administration (FDA). 16 September 2021. Archived from the original on 4 October 2021. Retrieved 5 November 2021. This article incorporates text from this source, which is in the public domain.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Anti-SARS-CoV-2 Monoclonal Antibodies". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 8 January 2022. Retrieved 8 January 2022.
↑ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.
↑ "Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab for Coronavirus Disease 2019 (COVID-19)". FDA. Archived from the original on 3 December 2021. Retrieved 8 January 2022.
↑ ^୭.୦ ^୭.୧ "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab". FDA. Archived from the original on 18 March 2021. Retrieved 8 January 2022.
↑ "Bamlanivimab". SPS - Specialist Pharmacy Service. 11 February 2021. Archived from the original on 19 November 2021. Retrieved 8 January 2022.
↑ "US to buy more doses of Lilly's Covid-19 antibody therapy". Pharmaceutical Technology. 1 March 2021. Archived from the original on 23 April 2021. Retrieved 8 January 2022.

[FDA_PR_20210209-1] "FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19". U.S. Food and Drug Administration (FDA) (Press release). 10 February 2021. Archived from the original on 10 February 2021. Retrieved 9 February 2021. This article incorporates text from this source, which is in the public domain.

[FDA_20210916-2] "FDA authorizes bamlanivimab and etesevimab for COVID-19". U.S. Food and Drug Administration. 16 September 2021. Archived from the original on 17 September 2021. Retrieved 16 September 2021.

[FDA_EUA-3] "Emergency Use Authorization 094" (PDF). U.S. Food and Drug Administration (FDA). 16 September 2021. Archived from the original on 4 October 2021. Retrieved 5 November 2021. This article incorporates text from this source, which is in the public domain.

[NIH2022Jan-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "Anti-SARS-CoV-2 Monoclonal Antibodies". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 8 January 2022. Retrieved 8 January 2022.

[NIHDec2021-5] "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 6 January 2022.

[FDA2021Side-6] "Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab for Coronavirus Disease 2019 (COVID-19)". FDA. Archived from the original on 3 December 2021. Retrieved 8 January 2022.

[EUA2022-7] ୭.୦ ^୭.୧ "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab". FDA. Archived from the original on 18 March 2021. Retrieved 8 January 2022.

[SP2022-8] "Bamlanivimab". SPS - Specialist Pharmacy Service. 11 February 2021. Archived from the original on 19 November 2021. Retrieved 8 January 2022.

[9] "US to buy more doses of Lilly's Covid-19 antibody therapy". Pharmaceutical Technology. 1 March 2021. Archived from the original on 23 April 2021. Retrieved 8 January 2022.

[୪]

[୫]

[୧]

[୨]

[୩]

[୬]

[୭]

[୮]

[୯]